Thrombectomy Devices Market Size to Exceed USD 3.24 Bn by 2032

The Thrombectomy Devices Market, estimated at USD 1.95 Bn in 2025, is expected to exhibit a CAGR of 7.5% and reach USD 3.24 Bn by 2032.

The industry is witnessing significant growth driven by rising demand for advanced, reliable, and cost-effective medical devices across diagnostic, therapeutic, and monitoring applications. Rapid advancements in device design, digital health integration, and adoption of minimally invasive technologies are reshaping the competitive landscape. Furthermore, supportive regulatory frameworks, increasing healthcare investments, and the growing focus on patient-centric care are expected to create new growth avenues for market players.

Key market players are focusing on adoption of growth strategies such as launch of new products that candrive the global thrombectomy devices market growth. For instance, in September 2025, Koninklijke Philips N.V., a global medical device company, announced the launch of Quicklear mechanical thrombectomy system. QuickClear is a compact, single-use system that is designed to provide an all-in-one aspiration pump and catheter for removing blood clots from the vessels of the peripheral arterial and venous systems.

Global Thrombectomy Devices Market– Impact of Coronavirus (COVID-19) Pandemic

The World Health Organization (WHO) designated the illness caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), which first appeared in Wuhan (province of Hubei, China), in the last months of 2025, as "coronavirus disease 2025" or COVID-19. This virus spreads quickly, and had a serious negative impact on the economies, social behaviors, and healthcare of every country in the world.

COVID-19 affected the economy in three main ways: by directly affecting production and demand, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to the lockdown, several countries such as India, China, Brazil, and others faced problems regarding transportation of things from one place to another. For instance, in November 2025, according to the data published by National Center for Biotechnology Information, COVID-19 is associated with increased risk of thromboembolic events. Mechanical thrombectomy (MT) is used to effectively manage large-vessel occlusive (LVO) stroke and has similarly been implemented in the management of stroke in COVID-19 patients. Thus, increasing thromboembolic events requires thrombectomy devices for the management.

Global Thrombectomy Devices Market: Key Developments

On June 7, 2025, Therma Bright Inc., a developer and partner in a wide-range of leading-edge, proprietary diagnostic and medical device technologies, and its investment partner Inretio Inc., a Israel based medical device company, announced the successful completion of a Good Laboratory Practice (GLP) study for its breakthrough PREVA mechanical thrombectomy device. This brings the PREVA device one step closer to human clinical trials and eventual market availability, marking a major advancement in the treatment of ischemic stroke.

For instance, in March 2025, Vetex Medical Ltd., a medical device company, announced that the U.S. Food and Drug Administration (FDA) had approved the ReVene thrombectomy catheter. ReVene uses dual-action technology, and is designed to de-clot peripheral vessels including deep vein thrombosis (DVT), in a single session without the use of thrombolytics.

Browse 37 Market Data Tables and 35 Figures spread through 180 Pages and in-depth TOC on “Global Thrombectomy Devices Market”- Forecast to 2032, Global Thrombectomy Devices Market, By Product Type (Mechanical thrombectomy Devices, Aspiration Thrombectomy Devices, Hydrodynamic Thrombectomy Devices, and Ultrasonic Thrombectomy Devices), By Application (Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Superficial Vein Thrombosis, Renal Vein Thrombosis (RVT), Arterial Thrombosis (Atherothrombosis), and Others (Ischemic stroke, etc.)), By End User (Hospitals, Ambulatory Surgical Centers, and Others (Academic and Research Institutes, etc.)), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

To know the latest trends and insights prevalent in this market, click the link below:

https://www.coherentmarketinsights.com/market-insight/thrombectomy-devices-market-2254

Key Takeaways of the Global Thrombectomy Devices Market:

Global thrombectomy devices market is expected to exhibit a CAGR of 7.5% during the forecast period. The merger with emerging economies such as China offers lucrative growth opportunities for players in the global thrombectomy devices market.
Among application, the deep vein thrombosis (DVT) segment is expected to hold a dominant position in the global thrombectomy devices market during the forecast period due to increasing launch of awareness campaign about deep vein thrombosis. For instance, in March 2025, The National Blood Clot Alliance (NBCA) announced the launch of awareness campaign to raise awareness among people about the increased risk of deep vein thrombosis.
Among region, North America is expected to be the dominant region in the global thrombectomy devices market, owing to increasing product approval by regulatory authorities. For instance, in January 2025, Penumbra Inc., a medical device company, announced that the U.S. Food and Drug Administration had approved the Indigo Aspiration System. As part of the system, Indigo Aspiration Catheters and Separators are indicated for the removal of fresh, soft emboli and thrombi from vessels of the peripheral arterial and venous systems, and now for the treatment of pulmonary embolism (PE).
Major players operating in the global thrombectomy devices market are Boston Scientific Corporation, Medtronic, Merit Medical System Inc., Stryker Corporation, Terumo Corporation, Teleflex Incorporated, Vetex Medical Ltd., Edwards Lifesciences Corporation, Penumbra Inc., Control Medical Technology, LLC., Rapid Medical, Abbott and Surmodics, Inc.